Stockreport

Incyte Gets FDA Approval for Rare-Blood-Cancer Treatment [MarketWatch]

Incyte Corporation  (INCY) 
Last incyte corporation earnings: 2/13 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: incyte.com/ir/investor-overview.aspx
PDF Pemazyre is a fibroblast growth factor receptor inhibitor, and has been approved to treat adults living with relapsed or refractory myeloid/lymphoid neoplasms with FGFR [Read more]